Business
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWS
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"Orphai Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Orphai Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/5d3d2638a6a5487c8e3d2c84a2694d57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8sTkg4rnhOKwXekKmssLBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Ng--/https://media.zenfs.com/en/globenewswire.com/5d3d2638a6a5487c8e3d2c84a2694d57","width":300,"height":133},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8sTkg4rnhOKwXekKmssLBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Ng--/https://media.zenfs.com/en/globenewswire.com/5d3d2638a6a5487c8e3d2c84a2694d57","width":300,"height":133}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeks","length":273,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":446,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented at the American Thoracic Society (ATS) conference in Orlando. The Company recently acquired LAM-001 through its previously announced acquisition of Orphai Therapeutics, Inc., a clinical-stage biotechnology company developing LAM-001 to treat rare pulmonary diseases","length":610,"tagName":"p"},{"type":"text","content":"The Phase 2a study was a 24-week, open-label trial conducted across four clinical sites evaluating LAM-001 as an add-on therapy to standard of care (SOC) in 10 adult patients with PAH and PH-ILD who remained sympt...